Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yasuyuki Kakurai

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Journal of Biopharmaceutical Statistics|November 6, 2014
A Dose-Finding Method Based on Multiple Dosing in Two-Agent Combination Phase I TrialsYasuyuki Kakurai, Akihiro Hirakawa, Chikuma Hamada
Pediatrics International : Official Journal of the Japan Pediatric Society|July 31, 2021
Sapropterin for phenylketonuria: A Japanese post-marketing surveillance studyMina Tamura, Shizuka Seki, Yasuyuki Kakurai, et al.
Journal of Pain Research|September 2, 2017
A randomized, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain reLief)Satoshi Inoue, Yoji Saito, Satoru Tsuneto, et al.
Clinical and Translational Science|November 19, 2025
Concentration-QTc Analysis of Valemetostat in Patients With Hematologic MalignanciesMasaya Tachibana, Bill Poland, Yasuyuki Kakurai, et al.
International Journal of Hematology|October 18, 2022
Phase I dose-escalation study of milademetan in patients with relapsed or refractory acute myeloid leukemiaNaohiro Sekiguchi, Senji Kasahara, Toshihiro Miyamoto, et al.
Cancer Science|March 9, 2021
Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I studyShunji Takahashi, Yutaka Fujiwara, Kenji Nakano, et al.
Journal for Immunotherapy of Cancer|August 16, 2019
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumorsKohei Shitara, Taroh Satoh, Satoru Iwasa, et al.
Clinical and Translational Science|October 28, 2025
Effect of Valemetostat on the Pharmacokinetics of Midazolam and Digoxin: A Phase 1 Drug-Drug Interaction Study in Patients With Non-Hodgkin LymphomaMasaya Tachibana, Steven Horwitz, Eric Jacobsen, et al.
Neuro-Oncology|November 9, 2025
Phase II study of safusidenib erbumine in patients with chemotherapy- and radiotherapy-naïve isocitrate dehydrogenase 1-mutated WHO grade 2 gliomasYoshiki Arakawa, Ryuta Saito, Yonehiro Kanemura, et al.
International Journal of Clinical Oncology|October 2, 2021
Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphomaKoji Kato, Shinichi Makita, Hideki Goto, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Journal of Biopharmaceutical Statistics|November 6, 2014
A Dose-Finding Method Based on Multiple Dosing in Two-Agent Combination Phase I TrialsYasuyuki Kakurai, Akihiro Hirakawa, Chikuma Hamada
Pediatrics International : Official Journal of the Japan Pediatric Society|July 31, 2021
Sapropterin for phenylketonuria: A Japanese post-marketing surveillance studyMina Tamura, Shizuka Seki, Yasuyuki Kakurai, et al.
Journal of Pain Research|September 2, 2017
A randomized, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain reLief)Satoshi Inoue, Yoji Saito, Satoru Tsuneto, et al.
Clinical and Translational Science|November 19, 2025
Concentration-QTc Analysis of Valemetostat in Patients With Hematologic MalignanciesMasaya Tachibana, Bill Poland, Yasuyuki Kakurai, et al.
International Journal of Hematology|October 18, 2022
Phase I dose-escalation study of milademetan in patients with relapsed or refractory acute myeloid leukemiaNaohiro Sekiguchi, Senji Kasahara, Toshihiro Miyamoto, et al.
Cancer Science|March 9, 2021
Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I studyShunji Takahashi, Yutaka Fujiwara, Kenji Nakano, et al.
Journal for Immunotherapy of Cancer|August 16, 2019
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumorsKohei Shitara, Taroh Satoh, Satoru Iwasa, et al.
Clinical and Translational Science|October 28, 2025
Effect of Valemetostat on the Pharmacokinetics of Midazolam and Digoxin: A Phase 1 Drug-Drug Interaction Study in Patients With Non-Hodgkin LymphomaMasaya Tachibana, Steven Horwitz, Eric Jacobsen, et al.
Neuro-Oncology|November 9, 2025
Phase II study of safusidenib erbumine in patients with chemotherapy- and radiotherapy-naïve isocitrate dehydrogenase 1-mutated WHO grade 2 gliomasYoshiki Arakawa, Ryuta Saito, Yonehiro Kanemura, et al.
International Journal of Clinical Oncology|October 2, 2021
Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphomaKoji Kato, Shinichi Makita, Hideki Goto, et al.
Pageof 2